In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America PerspectiveValeria Chu, Andrej Skerjanec, Heidi J. Einolf et al.|Drug Metabolism and Disposition|2009Cited by 161
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry PerspectiveTonika Bohnert, Louis Leung, Susanna Tse et al.|Drug Metabolism and Disposition|2016Cited by 110
Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction DataHeidi J. Einolf, Ping Zhao, L Chen et al.|Clinical Pharmacology & Therapeutics|2013Cited by 93
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive ControlNiresh Hariparsad, Donald Tweedie, Diane Ramsden et al.|Drug Metabolism and Disposition|2017Cited by 46
Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry PerspectiveOdette A. Fahmi, Mohamad Shebley, Jairam Palamanda et al.|Drug Metabolism and Disposition|2016Cited by 45